Abstract:Inhibition of the MDM2-p53 interaction is considered to be a new therapeutic strategy to activate wild-type p53 in tumors. Recently, a series of potent and specific small-molecule spiro-oxindole inhibitors of the MDM2 were reported. In the current study, the interaction modes between 21 spiro-oxindole MDM2 inhibitors and the protein were studied by using the combination of molecular docking, molecular dynamics simulation and three-dimensional quantitative structure-activity relationships (3D-QSAR). The QSAR predictive models were established by using comparative molecular field analysis (CoMFA) and comparative similarity indices analysis (CoMSIA) techniques. The predictive power of the 3D-QSAR models were determined from external test sets that were excluded during model development. The inhibitors in test sets were given exactly the same pretreatment as the inhibitors in the corresponding training sets. The correlation between the experimental and predicted activity for all models was calculated as a predictive r(2) value. With the CoMFA model, the cross-validated value (q(2)) was 0.573, the non-cross-validated value (r(2)) was 0.948. And with the CoMSIA model, the corresponding q(2) and r(2) were 0.651 and 0.98, respectively. The interaction mode obtained by molecular docking was in agreement with the results of molecular dynamics simulations, the interaction mode revealed that the hydrophobic interaction and H-bond played an important role in the binding of spiro-oxindole derivatives and MDM2. Compounds designed by our group were synthesized and tested their in vitro cytotoxic activities against the MDM2 positive prostatic carcinoma LNCaP cell line. Two compounds, namely 5 and 6, with favorable scores from the CoMFA and CoMSIA models, showed potent cytotoxic activities with IC50 values lower than 1.0 mu g.mL(-1). The result was corresponding with that in experiment. And it was very significance to discover novel spiro-oxindole inhibitors which are mainly aimed at the MDM2-p53 interaction. It was expected that the information provided here was helpful for the study toward more accurate structure based on 3D-QSAR modeling and anti-tumor drug design and discovery.

Effect of Mutations on Drug Resistance of Smoothened Receptor Toward Inhibitors Probed by Molecular Modeling

Deciphering the Allosteric Effect of Antagonist Vismodegib on Smoothened Receptor Deactivation Using Metadynamics Simulation.

Molecular Modeling Study on the Dynamical Structural Features of Human Smoothened Receptor and Binding Mechanism of Antagonist LY2940680 by Metadynamics Simulation and Free Energy Calculation.

Small Molecule Antagonists in Distinct Binding Modes Inhibit Drug-Resistant Mutant of Smoothened.

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds

Novel-smoothened Inhibitors for Therapeutic Targeting of Naïve and Drug-Resistant Hedgehog Pathway-Driven Cancers.

Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives As Potent Smoothened Antagonists with in Vivo Activity.

Design, Synthesis, and Structure–activity-Relationship of Tetrahydrothiazolopyridine Derivatives As Potent Smoothened Antagonists

Structural Optimization on a Virtual Screening Hit of Smoothened Receptor.

Discovery of Potent and Novel Smoothened Antagonists Via Structure-Based Virtual Screening and Biological Assays.

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Data analysis of molecular dynamics simulation trajectories of β-sitosterol, sonidegib and cholesterol in smoothened protein with the CHARMM36 force field

Effect of Double Mutations T790M/L858R on Conformation and Drug-Resistant Mechanism of Epidermal Growth Factor Receptor Explored by Molecular Dynamics Simulations

Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo

Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.

Overcoming the Resistance Mechanisms of Smoothened Inhibitors.

Structure-Activity Relationship Studies of Hydantoin-Cored Ligands for Smoothened Receptor.

Discovery of Novel Lysine Methyltransferase (SMYD3) Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

Molecular Docking, QSAR and Molecular Dynamics Simulation on Spiro-oxindoles As MDM2 Inhibitors